STAT January 6, 2025
Adam Feuerstein

Readouts are coming from Ultragenyx, Akero Therapeutics, and Incyte

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

Osteogenesis imperfecta, or OI, is a group of genetic disorders characterized by decreased bone mass and increased bone fragility. Ultragenyx is developing...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
How Pharmacy Deserts, Biosimilars, and Market Trends Are Shaping Managed Care
CVS Caremark taps Omada on GLP-1 program
Placing the patient at the centre of the drug development paradigm
Fostering clinician-led biotech innovation
InnovationRx: Trump Administration Health Agency Layoffs Threaten Biotech Innovation

Share This Article